Qi Xiaoyan, Qiao Boyang, Song Tingting, Huang Dan, Zhang Hui, Liu Yang, Jin Qi, Yang Ming, Liu Delong
Department of Breast Surgery, Liaoning Cancer Hospital & Institution, Shenyang, Liaoning, China.
Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China.
Front Oncol. 2023 Aug 30;13:1223786. doi: 10.3389/fonc.2023.1223786. eCollection 2023.
The newly discovered pan-immune-inflammation value (PIV) has been illustrated to have good prognostic value for cancer patient prognosis. However, the prognostic usefulness of PIV in breast cancer patients is unknown. As a result, to aid the clinic in providing a distinctive and trustworthy biomarker to better assess breast cancer patient's prognosis, we conducted this meta-analysis to investigate the relationship between PIV and the survival of breast cancer patients.
We conducted a systematic search of Pubmed, Embase, the Cochrane Library, and the CNKI databases to screen for eligible studies published up to April 2023. Outcomes included overall survival (OS), progression-free survival (PFS), and pathological complete response (pCR). The hazard ratio (HR) and the corresponding 95% confidence interval (CI) were used as the indicators. STATA 15.0 software was used to perform meta-analysis, sensitivity analysis, and publication bias analysis.
A total of eight articles, involving 2953 patients, met the inclusion criteria and were included in this meta-analysis. The results showed that patients with higher PIV levels had a significantly shorter OS (HR: 2.045, 95% CI: 1.355-3.086, = 0.001) and PFS (HR: 1.466, 95% CI: 1.163-1.848, = 0.001). Besides, the PIV value was negatively correlated with the efficacy of neoadjuvant chemotherapy. Sensitivity analysis showed that the results of this study were reliable and stable.
PIV has a good prognostic value in breast cancer patients and is expected to be a prognostic biomarker for breast cancer.
新发现的全免疫炎症值（PIV）已被证明对癌症患者的预后具有良好的预测价值。然而，PIV在乳腺癌患者中的预后实用性尚不清楚。因此，为了帮助临床提供一种独特且可靠的生物标志物，以更好地评估乳腺癌患者的预后，我们进行了这项荟萃分析，以研究PIV与乳腺癌患者生存率之间的关系。
我们对PubMed、Embase、Cochrane图书馆和中国知网数据库进行了系统检索，以筛选截至2023年4月发表的符合条件的研究。结局指标包括总生存期（OS）、无进展生存期（PFS）和病理完全缓解（pCR）。采用风险比（HR）及相应的95%置信区间（CI）作为指标。使用STATA 15.0软件进行荟萃分析、敏感性分析和发表偏倚分析。
共有8篇文章，涉及2953例患者，符合纳入标准并被纳入本荟萃分析。结果显示，PIV水平较高的患者OS（HR：2.045，95%CI：1.355 - 3.086，P = 0.001）和PFS（HR：1.466，95%CI：1.163 - 1.848，P = 0.001）显著缩短。此外，PIV值与新辅助化疗的疗效呈负相关。敏感性分析表明，本研究结果可靠且稳定。
PIV在乳腺癌患者中具有良好的预后价值，有望成为乳腺癌的一种预后生物标志物。
